Dendl, Katharina
Koerber, Stefan A.
Finck, Rebecca
Mokoala, Kgomotso M. G.
Staudinger, Fabian
Schillings, Lisa
Heger, Ulrike
Röhrich, Manuel
Kratochwil, Clemens
Sathekge, Mike
Jäger, Dirk
Debus, Jürgen
Haberkorn, Uwe
Giesel, Frederik L.
Article History
Received: 18 January 2021
Accepted: 22 April 2021
First Online: 29 May 2021
Declarations
:
: This retrospective study was approved by the local institutional review board.
: Patients provided a written informed consent.
: SAK reports grants from Viewray Inc., outside the submitted work.JD reports grants from Viewray Inc., CRI – The Clinical Research Institute GmbH, Accuray International Sari, RaySearch Laboratories AB, Vision RT Limited, Merck Serono GmbH, Astellas Pharma GmbH, Astra Zeneca GmbH, Siemens Healthcare GmbH, Solution Akademie GmbH, Ergomed PLC Surrey Research Park, Quintiles GmbH, Pharmaceutical Research Associates GmbH, Boehringer Ingelheim Pharma GmbH&CoKG, PTW-Freiburg Dr. Pychlau GmbH, Nanobiotix S.A, outside the submitted work.UH, CK, and FG are named in a patent application (EP 18155420.5) for quinolone-based FAP-targeting agents for imaging and therapy in nuclear medicine. CK, UH, and FLG also have shares of a consultancy group for iTheranostics.All other authors declare no potential conflicts of interest relevant to this article.